Jasper Therapeutics (NASDAQ: JSPR) is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (“MDS”) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (“SCD”), Fanconi anemia (“FA”) and severe combined immunodeficiency (“SCID”). To date, briquilimab has a demonstrated efficacy and safety profile in over 130 dosed subjects and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (“AML”), MDS, FA, and SCD. In addition, briquilimab is being advanced as a transformational non-genotoxic conditioning agent for gene therapy. For more information, visit the company’s website at www.jaspertherapeutics.com.
To view IBN’s coverage of the conference, visit https://ibn.fm/EFHutton2023
About IBN’s Coverage
IBN, a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the companies participating at the Inaugural EF Hutton Global Conference. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com